Chimerix Stock

Chimerix Enterprise Value

Delisted·Apr 17, 2025

The Enterprise Value (EV) of Chimerix (CMRX) as of Aug 26, 2026 is 770.03 M USD. In the previous year, Enterprise Value (EV) was 618.25 M USD — a change of 24.55% (higher).

Enterprise Value

770.03 MUSD

YoY

24.55%

Last updated:

Enterprise Value (EV) of Chimerix is 2026 770.03 M USD. Enterprise Value (EV) of Chimerix was 2025 618.25 M USD. It decreases by 24.55% higher compared to the previous year.

The Chimerix Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2017
649.56 M USD
Jan 1, 2018
614.55 M USD
Jan 1, 2019
687.61 M USD
Jan 1, 2020
722.12 M USD
Jan 1, 2021
726.71 M USD
Jan 1, 2022
583.75 M USD
Jan 1, 2023
618.25 M USD
Jan 1, 2024
770.03 M USD
The Chimerix Enterprise Value history
YEAREnterprise ValueYoY
770.03 MUSD+24.55%
618.25 MUSD+5.91%
583.75 MUSD-19.67%
726.71 MUSD+0.64%
722.12 MUSD+5.02%
687.61 MUSD+11.89%
614.55 MUSD-5.39%
649.56 MUSD+14.15%
569.06 MUSD-2.01%
580.75 MUSD+1.74%
570.80 MUSD
Access this data via the Eulerpool API

Chimerix Stock analysis

What does Chimerix do? Chimerix Inc is a biopharmaceutical company focused on the development of antiviral drugs. The company was founded in 2002 and is headquartered in Durham, North Carolina. The history of Chimerix dates back to the research of Dr. George Painter, a renowned scientist in the field of antiviral therapy. He discovered that a certain group of molecules, known as nucleoside analogues, have antiviral properties. The idea was to use these molecules as a starting point for the development of drugs that specifically target viruses. The core idea of Chimerix was to create a new business model that is different from traditional pharmaceutical companies. Instead of focusing on the lengthy and costly development of new compounds, the company wanted to utilize existing molecules and create new drugs through targeted modifications. This approach was not only expected to be faster and cost-effective but also to offer higher chances of success. Chimerix is divided into several business segments. The most important segment is antiviral therapy, where the company focuses on developing drugs against various viruses such as Cytomegalovirus (CMV), Adenovirus, and Herpesvirus. Another business segment of Chimerix is oncology. Here, the company also relies on modifying existing compounds to develop new and effective cancer drugs. One promising molecule currently being developed is Brincidofovir, which not only has antiviral properties but also possesses antitumor properties. In addition to drug development, Chimerix also offers support for clinical trials. The company collaborates with various research institutions and biopharmaceutical companies to test the efficacy and safety of new compounds. The most well-known product of Chimerix is Brincidofovir. This antiviral drug is currently being tested in clinical trials and has the potential to be used against a range of viruses. Its use is particularly promising in patients undergoing immunosuppressive therapy, such as those after a stem cell transplant. Chimerix aims to develop innovative and effective drugs that help patients overcome serious diseases. With its unique business model and close collaboration with the research community, the company has already made promising progress and is an important player in the field of antiviral therapy and oncology. Chimerix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Chimerix stock

Enterprise Value (EV) of Chimerix is 770.03 M USD in 2026.

Enterprise Value (EV) of Chimerix changed from 618.25 M USD to 770.03 M USD, representing a 24.55% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) Chimerix since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s USD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' USD varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s Chimerix with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Chimerix

All Key Metrics — Chimerix